Εμφανίζονται 1 - 18 Αποτελέσματα από 18 για την αναζήτηση '"функциональное состояние миокарда"', χρόνος αναζήτησης: 0,70δλ Περιορισμός αποτελεσμάτων
  1. 1
  2. 2
    Academic Journal
  3. 3
    Academic Journal

    Πηγή: Clinical and experimental pathology; Vol. 17 No. 1 (2018) ; Клиническая и экспериментальная патология; Том 17 № 1 (2018) ; Клінічна та експериментальна патологія; Том 17 № 1 (2018) ; 2521-1153 ; 1727-4338

    Περιγραφή αρχείου: application/pdf

  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
    Academic Journal

    Πηγή: Meditsinskiy sovet = Medical Council; № 4 (2014); 12-16 ; Медицинский Совет; № 4 (2014); 12-16 ; 2658-5790 ; 2079-701X ; undefined

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/537/537; Shigemitsu H, Nagai S, Sharma OP. Pulmonary hypertension and granulomatous vasculitis in sarcoidosis. Curr. Opin. Pulm. Med., 2007, 13: 434-8.; Battesti JP, Georges R, Basset F et al. Chronic cor pulmonale in pulmonary sarcoidosis. Thorax, 1978, 33: 76-84.; Rizzato G, Pezzano A, Sala G et al. Right heart impairment in sarcoidosis: haemodynamic and echocardiography study. Eur.JRespir. Dis, 1983, 64: 121-8.; Mayock RL, Bertrand P,Morrison CE et al. Manifestations of sarcoidosis. Analysis of 145 patients with a review of nine seriesselected from the literature. Am. J. Med., 1963, 35: 67-89.; Shorr AF, Helman DL, Davies DB et al. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur. Respir. J., 2005, 25: 783-788.; Orens JB, Estenne M, Arcasoy S et al. International guidelines for the selection of lung transplant candidates: 2006 update a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J. Heart Lung Transplant, 2006, 25: 745-755.; Baughman RP, Engel PJ, Taylor L et al. Survival in sarcoidosis associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest, 2010. DOI:10.1378/09-2002.; Baughman RP, Engel PJ, Meyer CA et al. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis, 2006, 23: 108-116.; Rosen Y, Moon S, Huang CT et al. Granulomatous pulmonary angiitis in sarcoidosis. Arch. Pathol. Lab. Med, 1977, 101: 170-174.; Takemura T, Matsui Y, Saiki S et al. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum. Pathol.,1992, 23: 1216-1223.; Sulica R, Teirstein AS, Kakarla S et al. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest, 2005, 128: 1483-1489.; Сперанская А.А. Комплексное компьютерно-томографическое и радионуклидное исследование в дифференциальной диагностике интерстициальных заболеваний легких. Дисс. канд. мед. наук. СПб., 2013.; Leuchte HH, Baumgartner RA, Nounou ME et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am. J. Respir. Crit. Care Med, 2006, 173: 744-750.; Corte TJ, Wort SJ, Gatzoulis MA et al. Elevated Brain natriuretic peptide predicts mortality in interstitial lung disease. Eur. Respir.)., 2010, 36: 819-25. DOI:10.1183/09031936.00173509.; Handa T, Nagai S, Shigematsu M et al. Patient characteristics and clinical features of Japanese sarcoidosis patients with low bronchoalveolar lavage CD4/ CD8 ratios. Sarcoidosis Vasc. Diffuse Lung Dis, 2005, 22: 154-160.; Baughman RP Pulmonary hypertension associated with sarcoidosis. Arthritis Res. Ther, 2007, 9 (Suppl. 2): S8.; Rodman DM, Lindenfeld J. Successful treatment of sarcoidosis associated pulmonary hypertension with corticosteroids. Chest, 1990, 97: 500-502.; Mangla A, Fisher J, Libby DM et al. Sarcoidosis, pulmonary hypertension, and acquired peripheral pulmonary artery stenosis. Cathet. Cardiovasc Diagn, 1985, 11: 69-74.; Gluskowski J, Hawrylkiewicz I, Zych D et al. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur. Respir. J, 1990, 3: 403-407.; Damuth TE, Bower JS, Cho K et al. Major pulmonary artery stenosis causing pulmonary hypertension in sarcoidosis. Chest, 1980, 78: 888-91.; Barst RJ, Ratner SJ. Sarcoidosis and reactive pulmonary hypertension. Arch. Intern. Med, 1985, 145: 2112-2114.; Fisher KA, Serlin DM, Wilson KC et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-termepoprostenol treatment. Chest, 2006, 130: 1481-1488.; Preston IR, Klinger JR, LandzbergMJ et al. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest, 2001, 120: 866-72.; Foley RJ, Metersky ML. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan. Respiration, 2008, 75: 211-14.; Sharma S, Kashour T, Philipp R. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. Tex. Heart Inst. J., 2005, 32: 405-10.; Pitsiou GG, Spyratos D, Kioumis I et al. Sarcoidosis-associated pulmonary hypertension: a role for endothelin receptor antagonists? Ther. Adv. Respir. Dis., 2009, 3: 99-101.; Robert P. Baughman MD, Daniel A. et al. Concise Review of Pulmonary Sarcoidosis. 3AJRCCM Articles in Press. Published on October 29, 2010 as doi:10.1164/rccm.201006-0865CI; Лебедева Е.В. Функциональное состояние миокарда и особенности гемодинамики малого круга кровообращения у больных саркоидозом легких по данным ЭХОКГ Дисс. канд. наук. СПб., 2004.; Перлей В.Е. Влияние повышенного внутригрудного давления на гемодинамику малого круга кровообращения. Дисс. канд. наук. Л., 1985.; Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J, 2009, 30: 2493-2537.; Амосов В.И., Сперанская А.А., Лукина О.В., Бобров Е.И. Мультиспиральная компьютерная томография в клиниках медицинского унивеситета. СПб.: ЭЛБИ-СПб., 2009.; undefined

  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18